Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 8/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.40 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.40 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967004 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Hydrochloric Acid SCHEMBL21518209 | 0.98 | SLC7A5 (0.54) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL21578343 | 0.82 | SLC7A5 (0.55) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL19951652 | 0.82 | SLC7A5 (0.54) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL18762560 | 0.82 | SLC7A5 (0.54) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Leucine SCHEMBL9119565 | 0.82 | SLC7A5 (0.72) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL197139 | 0.80 | SLC7A5 (0.48) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL196695 | 0.80 | SLC7A5 (0.48) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL197117 | 0.80 | SLC7A5 (0.48) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Hydrochloric Acid SCHEMBL21059082 | 0.78 | SLC7A5 (0.46) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-7662849-B2 | Amidino compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662849-B2 | Amidino compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662849-B2 | Amidino compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20070276019-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070276019-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070276019-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1761485-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| EP-1664003-A1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050288336-A1 | Cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | US | disclosed |
| EP-1569954-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005028454-A1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005028454-A1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004108661-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004108661-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040127426-A1 | Peptidic compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
| WO-2004052921-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052921-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288336-A1 | Cysteine protease inhibitors | CTSF, CTSS, CTSB | SLC7A5 964/4885SLC1A2 4320/4885SLC1A1 3678/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | SLC7A5 75/4885SLC1A2 236/4885SLC1A1 142/4885 |
| US-20040127426-A1 | Peptidic compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | SLC7A5 601/4885SLC1A2 4176/4885SLC1A1 3433/4885 |
| US-20070276019-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | CTSF, CTSS, CTSE | SLC7A5 568/4885SLC1A2 3836/4885SLC1A1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.